ClinicalTrials.gg
CompletedNCT00046423Updated Nov 25, 2016

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

A Phase 1 interventional study of ABI-007 in Neoplasms and Metastases, Neoplasm, sponsored by Celgene Corporation. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-25.

Primary conditionNeoplasm MetastasisRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Neoplasm Metastasis
Why
  1. The study's listed conditions name Neoplasm Metastasis, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis — 2 open to participants now, 2 under way, 1 of them phase 3. Albumin-Bound Paclitaxel · Neoplasm Metastasis.

Enrollment
16th of 23
20 · median 56
Started
2000
the only one that year
Phase 1
6 of 23
none open now
Registered
1st of 23
by date
Lead sponsor
3 of 23
Celgene Corporation

Among the 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis, this one is the 16th largest by enrollment, is the only one that started in 2000, is one of 6 in phase 1, and was the 1st registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

2 of the 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Albumin-Bound Paclitaxel in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. Patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. Treatment will be repeated in four week cycles if the patient improves on the therapy, and if there are no adverse events that require withdrawal of medication.

Read the detailed description

This will be a dose-escalating study. ABI-007 will be administered as an outpatient infusion for three weeks followed by a week of rest. The treatment course will repeat every 28 days. No pretreatment will normally be considered necessary. Patients will have white blood cell and platelet counts monitored as will indications of performance (Karnofsky Performance Status), and will be asked to describe adverse events, if present. Patients will be treated for a minimum of two cycles to be evaluable for the study, and may continue in the study for four cycles within the study, if tumor response and safety parameters warrant continuing. Patients may continue on study medication beyond this at the investigator's discretion.

03

Conditions studied

  • Neoplasms
  • Metastases, Neoplasm

Browse trials for

Keywords

  • Cancer
  • solid tumor
  • Advanced malignancy
  • Taxane therapy
  • Biopsy-proven diagnosis of advanced malignancy
  • Various solid tumors which are refractory
04

In context

Neoplasm Metastasis Reclassified

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

This study's enrollment of 20 is below the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.

First submitted before Celgene became part of Bristol-Myers Squibb.

Compared within Neoplasm Metastasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • At least 18 years of age
  • of at least 2 months
  • Off all therapy for at least 3 weeks prior to study drug administration
  • -proven diagnosis of advanced
  • Patients with solid tumors who have failed standard therapy
  • Performance Status of 70% or 0-2 SWOG Performance Status
  • at least 9
  • White Blood Cell count of at least 3000/mm3 with of at least 1500/mm3
  • count of at least 100,000/mm3
  • Serum Creatinine less than 2 mg/dL
  • Transaminases less than 3X the
  • Patient must provide
  • Serum less than 1.5 mg/dL
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants

Interventions

07

Study locations

1 site
  • Abraxis Bioscience, Inc.
    Durham, North Carolina 27703, United States
08

References and documents

Publications

  • Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005 Nov 1;23(31):7785-93. doi: 10.1200/JCO.2004.00.6148. PubMed 16258082 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00046423
Responsible party
Sponsor
First posted
Oct 3, 2002
Start date
Apr 2000
Last update
Nov 25, 2016

Study contacts

Michael J Hawkins, M.D.
study director · Celgene Corporation
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion